The integration of additional targeted agents with the induction regimen, such as ALK inhibitors for patients with ALK mutations or mTOR/MAPK inhibitors for those with an activated RAS-MAPK pathway, holds the potential to increase efficacy and broaden salvage alternatives for primary refractory HR-NB patients. The gene discussed is ALK; the disease is neuroblastoma.